CliffBio
small molecule

TYVASO

TREPROSTINIL

Loss of exclusivityFebruary 2042latest FDA-listed patent expiry
CompanyUnited Laboratories →See this company's full patent-cliff portfolio

Drug detail

Brand nameTYVASO
Active ingredientTREPROSTINIL
Strength0.6MG/ML
Dosage formSOLUTION
RouteINHALATION
ModalitySmall molecule
FDA approvalJuly 2009
Marketing statusRX

Listed patents

PatentExpiresType
11826327February 2042use U-3749
9593066December 2028substance
11723887December 2028substance
9358240May 2028use U-1849
9339507March 2028product
10376525May 2027use U-1849

More from United Laboratories

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TYVASO patent cliff — loss of exclusivity February 2042 | CliffBio